Doctor profile · Federal record
Dr. Miles Andrew, M.D.
Dermatology Physician (CMS: Dermatology) · Mishawaka, IN
- NPI 1689692188
- Accepts Medicare
- 35 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
230 E Day RD, Suite 130
Mishawaka, IN 465453408
(574) 335-7650
fax (574) 335-0736 - Mailing address
-
707 E Cedar St, Ste 200
South Bend, IN 466172057
Credentials & registration
- NPI registered
- July 2006 — 20 yrs on file
- Profile last updated
- September 14, 2016
- Year of graduation
- 1991 — 35 yrs since
- Specialty taxonomy
- 207N00000X — NUCC code
- State license (1)
- Indiana #01040450A
- Medicaid (2)
- IN #100380840A · IN #100380840
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1689692188. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
2,657
Distinct HCPCS
10
Medicare allowed
$168,810
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
17003 |
Destruction of precancer skin growth, 2-14 growths | 774 | 182 | $6 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 501 | 398 | $84 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 370 | 285 | $118 | |
17000 |
Destruction of precancer skin growth, 1 growth | 315 | 248 | $50 | |
17110 |
Destruction of skin growth, 1-14 growths | 222 | 185 | $103 | |
11102 |
Biopsy of related skin growth, first growth | 110 | 101 | $86 | |
99204 |
New patient office or other outpatient visit, 45-59 minutes | 63 | 63 | $153 | |
99203 |
New patient office or other outpatient visit, 30-44 minutes | 60 | 60 | $104 | |
J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 56 | 22 | $1 | |
99212 |
Established patient office or other outpatient visit, 10-19 minutes | 40 | 39 | $52 |
In context: peer comparison
Among 2 peers in Mishawaka Dermatology Physician, average services per provider: 129. This provider delivers 21× the peer median.Open Payments
Industry payments received
All-time total
$1,062
Transactions
56
Manufacturers
12
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Abbvie INC. | 13 | $242.74 | |
| Novartis Pharmaceuticals Corporation | 13 | $189.94 | |
| Janssen Biotech, INC. | 8 | $138.55 | |
| E.R. Squibb & Sons, L.L.C. | 5 | $104.33 | |
| Regeneron Healthcare Solutions, INC. | 2 | $69.26 | |
| Amgen INC. | 3 | $68.08 | |
| Lilly USA, LLC | 3 | $59.89 | |
| Ucb, INC. | 2 | $54.70 | |
| Genzyme Corporation | 3 | $51.60 | |
| Sun Pharmaceutical Industries INC. | 2 | $33.49 | |
| Incyte Corporation | 1 | $28.23 | |
| Mallinckrodt Hospital Products INC. | 1 | $21.18 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
858
Patients
398
Total drug cost
$244,857
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Ketoconazole | Generic | 175 | 85 | $4,366 |
| Fluorouracil | Generic | 102 | 89 | $12,665 |
| Triamcinolone Acetonide | Generic | 100 | 67 | $1,066 |
| Mometasone Furoate | Generic | 70 | 47 | $1,856 |
| Dapsone | Generic | 58 | 0 | $2,122 |
| Clindamycin Phosphate | Generic | 41 | 22 | $1,381 |
| Otezla (Apremilast) | Brand | 41 | 0 | $206,583 |
| Gabapentin | Generic | 38 | 13 | $365 |
| Metronidazole | Generic | 38 | 17 | $3,580 |
| Fluticasone Propionate | Generic | 37 | 19 | $1,147 |
Frequently asked questions
What is Dr. Miles Andrew's medical specialty?
Dr. Miles Andrew practices Dermatology Physician in Mishawaka, IN.
Where does Dr. Miles Andrew practice?
Dr. Miles Andrew practices at 230 E Day RD, Mishawaka, IN 465453408. Office phone: 5743357650.
What is Dr. Miles Andrew's NPI?
Dr. Miles Andrew's National Provider Identifier (NPI) is 1689692188, issued by NPPES.
Does Dr. Miles Andrew accept Medicare assignment?
Yes. Dr. Miles Andrew accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Miles Andrew commonly perform?
Top Medicare-reported procedures in 2023: Destruction of precancer skin growth, 2-14 growths (HCPCS 17003); Established patient office or other outpatient visit (HCPCS 99213); Established patient office or other outpatient visit (HCPCS 99214). Source: CMS Medicare Physician & Other Practitioners file.